TSS
LCTX icon

Two Sigma Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

Two Sigma Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.5K Buy
37,793
+17,403
+85% +$24K ﹤0.01% 1389
2026
Q1 		$32.2K Sell
20,390
-3,208
-14% -$5.41K ﹤0.01% 1317
2025
Q4 		$39.4K Buy
+23,598
New +$40.8K 0.01% 1106
2025
Q3 		– Sell
-18,028
Closed -$16.4K – 1746
2025
Q2 		$16.4K Buy
+18,028
New +$10.7K ﹤0.01% 1241
2024
Q4 		– Sell
-13,941
Closed -$12.6K – 2496
2024
Q3 		$12.6K Buy
+13,941
New +$12.9K ﹤0.01% 2557
2024
Q1 		– Sell
-12,704
Closed -$13.8K – 3315
2023
Q4 		$13.8K Buy
+12,704
New +$13.9K ﹤0.01% 2778
2023
Q2 		– Sell
-16,538
Closed -$24.8K – 3100
2023
Q1 		$24.8K Sell
16,538
-782
-5% -$1.09K ﹤0.01% 2336
2022
Q4 		$20.3K Buy
+17,320
New +$21.8K ﹤0.01% 2278
2021
Q4 		– Sell
-96,762
Closed -$244K – 1815
2021
Q3 		$244K Buy
+96,762
New +$248K 0.01% 1116
2018
Q4 		– Sell
-14,906
Closed -$31K – 2527
2018
Q3 		$31K Buy
+14,906
New +$31.3K ﹤0.01% 2394

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Two Sigma Securities's LCTX Position: Q2 2026 in Review

Two Sigma Securities increased its Lineage Cell Therapeutics (LCTX) stake by 85% in Q2 2026, buying an estimated $24K and bringing the position to 37,793 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1389.

Two Sigma Securities first reported a position in LCTX in Q3 2018 and has held it in 10 quarters since. The position peaked at $244K in Q3 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Two Sigma Securities held 37,793 shares of Lineage Cell Therapeutics worth $49.5K as of Q2 2026.
  • Two Sigma Securities bought 17,403 Lineage Cell Therapeutics shares in Q2 2026, an estimated $24K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1389 holding.
  • Two Sigma Securities first reported a position in Lineage Cell Therapeutics in Q3 2018 and has held it in 10 quarters since.
  • Two Sigma Securities's Lineage Cell Therapeutics position peaked at $244K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.